BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia

Published:2020 Issue:8 Volume:11 Page:2234-2240
ISSN:1837-9664
Container-title:Journal of Cancer
language:en
Short-container-title:J. Cancer

Author:

Cai Zhimei,Jia Xiting,Zi Jie,Song Huihui,Wang Shujun,McGrath Mary,Zhao Lidong,Song Chunhua,Ge Zheng

Publisher

Ivyspring International Publisher

Subject

Oncology

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Response Assessment in Patients with Chronic Myeloid Leukemia; Clinicopathological Retrospective Research;Meandros Medical and Dental Journal;2022-12-29

2. Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels;Turkish Journal of Hematology;2022-08-24

3. Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients;Cancer Management and Research;2021-06

4. Overlooking the obvious? On the potential of treatment alterations to predict patient-specific therapy response;Experimental Hematology;2021-02

5. Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment;ecancermedicalscience;2020-08-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP